Drag a card by its title · ⚙ to size, swap or remove

The company

BridgeBio Pharma, Inc.

BBIO · Nasdaq

Health CareBiotechnologyNot moving yet

BBIO stood above a rising 150-day average in 38 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 7.0% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 6
Industry in uptrend: 16% -15 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $194.7M
Officials’ trades on record: 9
Institutions holding: 460 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 38 of 52 weeks.

20 Apr – 19 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

9 disclosed lines: House 8, Senate 0, executive 1; 2 people.

Who	Did	Amount	Traded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	sold	$1k–$15k	29 Sep 2026filed 12 Oct 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	bought	$1k–$15k	18 May 2026filed 1 Jul 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	bought	$1k–$15k	11 May 2026filed 8 Jun 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	bought	$1k–$15k	29 Apr 2026filed 8 May 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	bought	$1k–$15k	19 Mar 2026filed 7 Apr 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	bought	$1k–$15k	18 Mar 2026filed 7 Apr 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	bought	$1k–$15k	3 Mar 2026filed 7 Apr 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	bought	$1k–$15k	22 Sep 2025filed 10 Oct 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31	bought	$1k–$15k	8 Aug 2025filed 12 Sep 2025

Insiders

Buy orders, 12 months0

Sale orders, 12 months50

Buyers · sellers0 · 10

Who	Did	Shares	Traded
Neil KumarChief Executive Officer	sold	8,721at $69.01	17 Sep 2026filed 21 Sep 2026
Neil KumarChief Executive Officer	sold	1,279at $69.57	17 Sep 2026filed 21 Sep 2026
Neil KumarChief Executive Officer	sold	8,100at $83.86	19 Aug 2026filed 20 Aug 2026
Neil KumarChief Executive Officer	sold	1,800at $84.69	19 Aug 2026filed 20 Aug 2026
Neil KumarChief Executive Officer	sold	100at $85.65	19 Aug 2026filed 20 Aug 2026
Neil KumarChief Executive Officer	sold	1,900at $81.15	18 Aug 2026filed 20 Aug 2026
Neil KumarChief Executive Officer	sold	17,279at $82.21	18 Aug 2026filed 20 Aug 2026
Neil KumarChief Executive Officer	sold	14,602at $82.99	18 Aug 2026filed 20 Aug 2026
Neil KumarChief Executive Officer	sold	1,199at $83.77	18 Aug 2026filed 20 Aug 2026
Maricel ApuliChief Accounting Officer	sold	2,000at $80.06	30 Jul 2026filed 3 Aug 2026
Jennifer E. CookDirector	sold	36,167at $84.00	9 Jul 2026filed 13 Jul 2026
Jennifer E. CookDirector	sold	112,422at $90.00	9 Jul 2026filed 13 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders460+4 on the quarter

New · exited78 · 75

Reported value$14.6B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Cormorant Asset Management, LPreduced · filed 14 Aug 2026	18,428,594$177.2M	-300,000−1.6%
Jupiter Topco LLCnew · filed 14 Aug 2026	14,110,278$1.1B	+14,110,278
Kohlberg Kravis Roberts & Co. L.P.unchanged · filed 14 Aug 2026	13,260,971$987.7M	00.0%
BlackRock, Inc.reduced · filed 7 Aug 2026	12,441,196$782.6M	-3,854,858−23.7%
FARALLON CAPITAL MANAGEMENT, L.L.C.added · filed 14 Aug 2026	10,743,063$800.1M	+1,377,600+14.7%
VIKING GLOBAL INVESTORS LPreduced · filed 14 Aug 2026	9,949,219$741.0M	-1,893,215−16.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	9,904,622$603.6M	+1,606,686+19.4%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026	8,098,226$416.7M	+2,795,925+52.7%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026	7,656,722$570.3M	-423,851−5.2%
CITADEL ADVISORS LLCadded · filed 14 Aug 2026	6,377,855$300.0M	+675,153+11.8%

31 Mar 2023 – 30 Jun 2026

News

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)manilatimes.net · 16 Oct 2026 BBIO - BridgeBio Pharma Inc Analysismorningstar.com · 1 Oct 2026

Everyone who traded it

Gilbert Ray Cisneros, Jr. CA31 · last 29 Sep 20267 · 1

Neil Kumar Chief Executive Officer · last 17 Sep 20260 · 74

Maricel Apuli Chief Accounting Officer · last 16 Aug 20260 · 7

Thomas Trimarchi President and CFO · last 16 Aug 20260 · 5

Andrea Ellis Director · last 9 Jul 20261 · 5

Jennifer E. Cook Director · last 9 Jul 20260 · 4

Hannah Valantine Director · last 23 Jun 20265 · 12

Ali J. Satvat Director · last 22 Jun 20260 · 0

Andrew Lo Director · last 22 Jun 20262 · 3

Charles J. Homcy Director · last 22 Jun 20260 · 8

Douglas A. Dachille Director · last 22 Jun 20263 · 0

Eric Aguiar Director · last 22 Jun 20260 · 0

Same industry

MRNA ModernaLeading+154%

IOVA Iovance BiotherapeuticsLeading+133%

ABCL AbCellera BiologicsLeading+61%

ENTX Entera BioLeading+49%

HALO Halozyme TherapeuticsLeading+46%

XERS Xeris Biopharma HoldingsLeading+46%

HELP Helus PharmaLeading+37%

XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202595.8%

Operating profit marginFY 2025 · to 31 Dec 2025-104%

Free cash flow marginFY 2025 · to 31 Dec 2025-89.0%

Return on capital employedFY 2025 · to 31 Dec 2025-80.8%

Research spendFY 2025 · to 31 Dec 202590.0%

Share count trendFY 2025 · to 12 Feb 2026-0.5%

Cash and equivalentsFY 2025 · to 31 Dec 2025$570.1M

Free cash flowFY 2025 · to 31 Dec 2025−$447.0M

Analyst forecasts

No analyst forecasts yet.